Nanobiotix S a (NBTX) - News Archive

Expanding Horizons in Cancer Treatment: A Deep Dive into Nanobiotix s JNJ-1900 (NBTXR3) Developments Cancer treatment continues to evolve with an increasing focus on innovative therapies that can enhance existing treatm...

Overview of NBTXR3 Phase 1 Study in Pancreatic CancerNanobiotix, a late-clinical stage biotechnology company, has recently announced the completion of its Phase 1 study evaluating JNJ-1900, also known as NBTXR3, in pati...

In the evolving landscape of biotechnology, where innovation and investor confidence intertwine, recent developments at Nanobiotix S.A. highlight the company’s commitment to sustainability and efficiency in the flotatio...

The flotation cell market is poised for transformative growth over the coming decade, evident from projections estimating its revenue to reach USD 554.7 million by 2033, reflecting a steady compound annual growth rate (...

In a landscape riddled with challenges and fierce competition, the battle against advanced non-small cell lung cancer (NSCLC) takes a promising turn with a novel therapeutic approach spearheaded by NANOBIOTIX. On Januar...

In the realm of global business, corporate governance and financial transparency remain pivotal elements that uphold market confidence and attract investment. This is exemplified by companies trading in public markets,...

On December 9, 2024, Nanobiotix, a clinical-stage biotechnology company known for pioneering therapies in nanomedicine, announced a significant advancement in its pancreatic cancer study, particularly focusing on its pr...

Nanobiotix s NBTXR3 Phase 1 Study: A Promising Step Forward Amidst Market Volatility Nanobiotix, an innovative biotechnology firm known for its pioneering work in nanoparticle-based therapeutic approaches, has recently...

In accordance with s L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers), understanding the impact on shareholders fo...

Nanobiotix, a leading biotechnology company, has recently announced compelling new data for its nanoparticle-based therapeutic approach, NBTXR3, in the treatment of advanced solid and metastatic tumors. The company pres...

for CSIMarket.com NANOBIOTIX, a late-clinical-stage biotechnology company, has recently unveiled significant findings from their ongoing Phase 1 study, known as Study 1100, at the 2024 Annual Meeting of the American Soc...

Nanobiotix, a late-clinical stage biotechnology company, is revolutionizing cancer treatment and addressing major diseases through nanoparticle-based therapeutic approaches. The company recently unveiled updates to its...

In accordance with s L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers), Nanobiotix S.A., a pioneering company in na...

NBTXR3: A Nanoparticle-Based Breakthrough in the Treatment of Stage Three Lung CancerLung cancer remains a significant health concern worldwide, with non-small cell lung cancer (NSCLC) being the most common type. While...

The voting rights and shares capital of Nanobiotix S.A: A closer look at the financial performanceIn a recent press release, Nanobiotix S.A announced key information regarding its voting rights and shares capital. Accor...

Nanobiotix, a leading biotechnology company specializing in physics-based approaches to revolutionize cancer treatment, has recently achieved a significant milestone in their ongoing global Phase 3 study. The study aims...

Voting Rights and Share Capital of the Company: Fairfax Announces Acquisition of Additional Orla SharesToronto-based Fairfax Financial Holdings Limited (Fairfax) has recently made a significant move in the mining indust...

Toronto-based Fairfax Financial Holdings Limited (Fairfax) announced its recent acquisition of 500,000 common shares of Orla Mining Ltd. through its insurance company subsidiaries. The purchase of the common shares, pri...

Nanobiotix s Groundbreaking Cancer Treatment, NBTXR3, Gains Momentum in Asian MarketsParis and Cambridge, Mass. - In a significant development, Nanobiotix, a renowned biotechnology company focused on advancing innovativ...

In a recent press release, Nanobiotix S.A. disclosed crucial information pertaining to the company s voting rights and shares capital. As per the regulations set forth by the French Commercial Code and the General Regul...